# US 2021/0263017 A1 · Methods, Reagents and Kits for Flow Cytometric Immunophenotyping

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0263017 A1
- Document ID: US20210263017A1
- Status: Published application
- Kind: A1
- Application number: 17/195,416
- Filed: 2021-03-08
- Published: 2021-08-26
- Earliest claimed: 2009-06-03
- Assignees: Erasmus University Medical Center Rotterdam
- Applicants: Erasmus University Medical Center Rotterdam
- Inventors: Jacobus Johannes Maria van Dongen; José Alberto Orfao de Matos Correia e Vale; Juan Alejandro Flores-Montero; Julia Maria Almeida Parra; Vincent Henricus Johannes van der Velden; Sebastian Böttcher; Andrew Craig Rawstron; Ruth Mary de Tute; Ludovic Bernard Simon Lhermitte; Vahid Asnafi; Ester Mejstríková; Tomasz Szczepanski; Paulo Jorge Monteiro Da Silva Lucio; Marta Martín Ayuso; Carlos Eduardo Pedreira
- Web page: https://patentgrep.com/patent/US20210263017A1

## CPC

- G01N 33/56972: {White blood cells}
- G01N 15/14: Optical investigation techniques, e.g. flow cytometry
- G01N 33/4915: {using flow cells (flow cytometry G01N15/14)}
- G01N 33/5005: {involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025)}
- G01N 33/5091: {for testing the pathological state of an organism}
- G01N 33/5094: {for blood cell populations (red blood cells G01N33/80)}
- G01N 33/532: Production of labelled immunochemicals
- G01N 33/533: with fluorescent label
- G01N 2015/1402: {Data analysis by thresholding or gating operations performed on the acquired signals or stored data}
- G01N 2015/1413: {Hydrodynamic focussing}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to the field of flow cytometry and more particularly to a panel of antibody reagents conjugated to fluorescent compounds. Provided are reagent compositions, comprising at least eight distinct fluorochrome-conjugated antibodies comprising a set of at least there identification antibodies for the identification of a leukocyte population of interest and at least four characterization antibodies for further characterization and/or classification of said leukocyte population. Also provided are kits and methods related to the reagent compositions.

## Claims

### Claim at position 1

-13. (canceled)

### Claim 14

A reagent composition for flow cytometric immunophenotyping and characterization of lymphoid cell subpopulations, wherein the reagent composition comprises antibodies against the markers human leukocyte antigen-DR (HLADR), CD45, CD34 and CD117, and wherein the reagent composition consists essentially of fluorochrome-conjugated antibodies are directed against one of the following combinations of markers:
(i) HLADR, CD45, CD16, CD13, CD34, CD117, CD11b and CD10, wherein the antibody against HLADR, the antibody against CD45, the antibody against CD16, the antibody against CD13, the antibody against CD34, the antibody against CD117, the antibody against CD11b, and the antibody against CD19 are each conjugated to a fluorochrome that has a different fluorescence emission from the other fluorochromes;
(ii) HLADR, CD45, CD35, CD64, CD34, CD117, immune receptor expressed by myeloid cells-2 (IREM2) and CD14, wherein the antibody against HLADR, the antibody against CD45, the antibody against CD35, the antibody against CD64, the antibody against CD34, the antibody against CD117, the antibody against IREM2, and the antibody against CD14 are each conjugated to a fluorochrome that has a different fluorescence emission from the other fluorochromes;
(iii) HLADR, CD45, CD36, CD105, CD34, CD117, CD33 and CD71, wherein the antibody against HLADR, the antibody against CD45, the antibody against CD36, the antibody against CD105, the antibody against CD34, the antibody against CD117, the antibody against CD33, and the antibody against CD71 are each conjugated to a fluorochrome that has a different fluorescence emission from the other fluorochromes;
(iv) HLADR, CD45, CD15, neuron-glial antigen-2 (NG2), CD34, CD117, CD7 and CD38, wherein the antibody against HLADR, the antibody against CD45, the antibody against CD15, the antibody against NG2, the antibody against CD34, the antibody against CD117, the antibody against CD7, and the antibody against CD38 are each conjugated to a fluorochrome that has a different fluorescence emission from the other fluorochromes;
(v) HLADR, CD45, CD42a, CD61, CD203c, CD34, CD117, CD123 and CD4, wherein the antibodies against CD42a and CD61 are conjugated to the same fluorochrome, and wherein the antibody against HLADR, the antibody against CD45, the antibody against CD203c, the antibody against CD34, the antibody against CD117, and the antibody against CD4 are each conjugated to a fluorochrome that has a different fluorescence emission from the other fluorochromes;
(vi) HLADR, CD45, CD41, CD25, CD34, CD117, CD42b and CD9, wherein the antibody against HLADR, the antibody against CD45, the antibody against CD41, the antibody against CD25, the antibody against CD34, the antibody against CD117, the antibody against CD42b, and the antibody against CD9 are each conjugated to a fluorochrome that has a different fluorescence emission from the other fluorochromes; or
(vii) HLADR, CD45, Terminal deoxynucleotidyl transferase (TdT), CD56, CD34, CD117, CD22 and CD19 wherein the antibody against HLADR, the antibody against CD45, the antibody against TdT, the antibody against CD56, the antibody against CD34, the antibody against CD117, the antibody against CD22, and the antibody against CD19 are each conjugated to a fluorochrome that has a different fluorescence emission from the other fluorochromes.

### Claim 15 (depends on 14)

A set of reagent compositions comprising two or more reagent compositions according to claim 14.

### Claim 16 (depends on 15)

The set of reagent compositions according to claim 15, comprising two or more reagent compositions selected from (i) through (iv).

### Claim 17 (depends on 15)

The set of reagent compositions according to claim 15, comprising three or more reagent compositions selected from (i) through (iv).

### Claim 18 (depends on 15)

The set of reagent compositions according to claim 15, comprising each of the reagent compositions of (i) through (iv).

### Claim 19 (depends on 15)

The set of reagent compositions according to claim 15, comprising two or more reagent compositions selected from (i) through (iv), and one or more reagent composition(s) selected from (v) through (vii).

### Claim 20 (depends on 15)

The set of reagent compositions according to claim 15, comprising each of the reagent compositions of (i) through (iv), and one or more reagent composition(s) selected from (v) through (vii).

### Claim 21 (depends on 14, 15)

The reagent composition or set of reagent compositions according to claim 14 or 15, wherein each reagent composition comprises antibodies conjugated to pacific blue (PacB) or Horizon V450, pacific orange (PacO) or AMCA, fluorescein isothiocyanate (FITC) or Alexa488, phycoerythrin (PE), peridinin chlorophyl protein/cyanine 5.5 (PerCP-Cy5.5), PerCP or PE-TexasRed, phycoerythrin/cyanine7 (PE-Cy7), allophycocyanine (APC) or Alexa647, and allophycocyanine/H7 (APC-H7), APC-Cy7, Alexa680 or Alexa700.

### Claim 22 (depends on 15)

A diagnostic kit for flow cytometric immunophenotyping of lymphoid cell subpopulations, comprising the set of at least two reagent compositions according to claim 15, optionally together with instructions for use, buffer, and/or control samples.

### Claim 23 (depends on 22)

The diagnostic kit according to claim 22 for the diagnosis of acute myeloid lymphoma (AML), comprising each of the reagent compositions of (i) through (v).

### Claim 24 (depends on 22)

The diagnostic kit according to claim 22 for the diagnosis and subclassification of acute myeloid lymphoma (AML), comprising each of the reagent compositions of (ii) through (v).

### Claim 25 (depends on 15, 22)

The diagnostic kit according to claim 22 for the identification and characterization of myeloid malignancies, comprising the set of reagent compositions according to claim 15.

### Claim 26 (depends on 22)

The diagnostic kit according to claim 22 for providing information about megakaryocytic, basophilic, and plasmacytoid dendritic lineages, comprising the reagent composition of (v).

### Claim 27 (depends on 22)

The diagnostic kit according to claim 22 for providing information for the diagnosis of mastocytosis, comprising the reagent composition of (vi).

### Claim 28 (depends on 22)

The diagnostic kit according to claim 22 for the characterization of AML/MDS, comprising at the reagent composition(s) of (vi) and/or (vii).

### Claim 29 (depends on 2)

A method for flow cytometric immunophenotyping and characterization of lymphoid cell subpopulations, comprising the steps of
(a) providing a biological sample comprising lymphoid cells;
(b) contacting a first aliquot of said sample with a first reagent composition of the set according to claim 2 and contacting at least a second aliquot of said sample with a further reagent composition of said set;
(c) analyzing lymphoid cells in said aliquots in a flow cytometer; and
(d) storing and evaluating the data obtained to characterize the lymphoid cells for the presence of normal and aberrant subpopulations.

### Claim 30 (depends on 29)

The method according to claim 29, wherein said sample is peripheral blood, bone marrow, tissue sample, or a body fluid.

### Claim 31 (depends on 29)

The method according to claim 29, wherein step (c) comprises the use of software for data integration and multidimensional analysis of flow cytometry files.

### Claim 32 (depends on 29)

The method according to claim 29, wherein said software is INFINICYT™.
